Cipla USA, Inc. 2026-03-11 Health moderate FDA
Health · FDA · Recall #FDA-D-0381-2026
Nilotinib Capsules, 150 mg per capsule, packaged in cartons, Rx only, Manufactured by:… Recall
Issued March 11, 2026 · Cipla USA, Inc.
In March 2026, Cipla USA, Inc. recalled the Nilotinib Capsules, 150 mg per capsule, packaged in cartons, Rx only, Manufactured by:…, a moderate health recall reported by the FDA.
Compiled by Maya Ellison, RecallCheckr
What this means for you
Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.
What you should do
- 1 Stop using Nilotinib Capsules, 150 mg per capsule, packaged in cartons, Rx only, Manufactured by:… right away.
- 2 Set it aside where it won't be used by mistake.
- 3 Contact Cipla USA, Inc. to arrange your voluntary. See the official notice below for contact details.
- 4 Keep the product until your remedy is fully processed. You may need it.
Official remedy (Voluntary):
Recall details
- Brand
- Cipla USA, Inc.
- Category
- Health
- Recall date
- March 11, 2026
- Units affected
- Not reported
- Sold at
- U.S.A. Nationwide
- Recall number
- FDA-D-0381-2026
- Made in
- United States
- Issuing agency
- FDA
In context
- Cipla USA, Inc. has 9 recalls in our database.
- We're tracking 3,576 Health recalls in our database.
- This is the 356th Health recall we've logged in 2026.